Drug Discovery & Pharmaceuticals

RSS

Scientists discover irreversible peptide inhibitors for undruggable cancer target

For the first time scientists have identified promising drug candidates that bind irreversibly with a notoriously "undruggable" cancer protein target, permanently blocking it.

20 Mar 2025

Sapio Sciences makes AI-Native drug discovery seamless with NVIDIA BioNeMo

Sapio Sciences, the science-aware™ lab informatics platform, today announced the integration of the NVIDIA BioNeMo platform into the Sapio Lab Informatics Platform.

From Sapio Sciences 20 Mar 2025

UCLA Health discovers drug that mimics stroke rehabilitation effects in mice

A new study by UCLA Health has discovered what researchers say is the first drug to fully reproduce the effects of physical stroke rehabilitation in model mice, following from human studies.

19 Mar 2025

Biomanufacturing platform offers a sustainable alternative to synthesizing peptide-based pharmaceuticals

To tackle the inequity in medication access, a societal issue especially in developing nations, a team of undergraduate student-researchers at the University of Ottawa has developed a new biomanufacturing platform called Phytogene.

18 Mar 2025

LGM Pharma invests $6 M in U.S. drug manufacturing capabilities for liquids, suspensions, semi-solids, and suppositories

LGM Pharma, a leading provider of tailored API and CDMO services for the full drug product lifecycle, today announced an investment of over $6 million to expand its Rosenberg, Texas manufacturing facility as part of its Phase I CDMO growth strategy.

13 Mar 2025

Shift Biosciences announces key appointments to advance rejuvenation therapeutics pipeline

Shift Biosciences, a biotech company using an AI powered virtual cell to fight age-related diseases, today announced the appointments of Jill Reckless, Ph.D, as Translation Advisor and Laurence Reid, Ph.D., as Non-Executive Director. In these roles, Jill and Laurence will guide Shift in building a robust product translation and business development strategy respectively, enabling the Company to capitalize on early momentum and progress its pipeline of novel rejuvenation therapeutics towards clinical development.

12 Mar 2025

New automated system revolutionizes drug evaluation in zebrafish

Preclinical drug evaluation, especially for cardiotoxicity, is a critical stage in the drug development process.

11 Mar 2025

British scientists unveil world-leading technology to speed up drug discovery

A new 3D bio-printer that produces human-like tissue holds the potential to revolutionize the discovery of new drugs for cancer, heart disease and arthritis.

10 Mar 2025

Vanderbilt researchers aim to use AI to develop antibody therapies for any target

An ambitious project led by Vanderbilt University Medical Center investigators aims to use artificial intelligence technologies to generate antibody therapies against any antigen target of interest.

8 Mar 2025

New drug VIP36 shows promise in treating pain without harmful side effects

A research team funded by the National Institutes of Health (NIH) has developed a medication that shows promise in treating acute and chronic pain.

5 Mar 2025

New chemical reaction enables precise functionalization of peptides and proteins

Pharmaceutical scientists at the National University of Singapore (NUS) have developed a novel chemical reaction that enables the precise functionalization of peptides and proteins.

28 Feb 2025

Microphysiological systems in drug discovery

NewsMedical speaks with CN Bio about the translatability between in vitro organ-on-a-chip (OOC) models, microphysiological systems, and their in vivo counterparts.

From CN Bio Innovations Ltd 26 Feb 2025

New antibody-toxin conjugate designed to stimulate immune-mediated eradication of tumors

Researchers at The University of Texas MD Anderson Cancer Center have developed a novel antibody-toxin conjugate (ATC) designed to stimulate immune-mediated eradication of tumors.

25 Feb 2025

Insilico Medicine reaches preclinical milestone in MASH drug discovery

Insilico Medicine("Insilico"), a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, recently achieved preclinical milestone in its collaboration with Therasid Bioscience, a South Korean based biotechnology company focuses on developing innovative first-in-class drugs for treatment for metabolic dysfunction-associated steatohepatitis (MASH).

25 Feb 2025

New antibiotic design could end the arms race with resistant bacteria

There's an arms race in medicine – scientists design drugs to treat lethal bacterial infections, but bacteria can evolve defenses to those drugs, sending the researchers back to square one.

24 Feb 2025

Breakthrough method opens door to fluorinated oxetane drug molecules

Researchers from the National University of Singapore (NUS) have pioneered a new catalytic transformation that converts epoxides into fluorinated oxetanes, a coveted but difficult-to-make class of drug molecules that escaped synthetic preparation for years.

22 Feb 2025

New computational tool iDOMO improves prediction of drug synergy

Researchers at the Icahn School of Medicine at Mount Sinai have developed a powerful computational tool, named iDOMO, to improve the prediction of drug synergy and accelerate the development of combination therapies for complex diseases.

22 Feb 2025

AI-driven discovery unveils TNIK inhibition as anti-aging strategy

A groundbreaking study led by researchers at Insilico Medicine has revealed the potential of TNIK inhibition as an innovative anti-aging strategy.

22 Feb 2025

Harbour BioMed partners with Insilico to accelerate AI-powered antibody discovery

Harbour BioMed (HKEX: 02142, the "Company"), a global biopharmaceutical company committed to the discovery, development and commercialization of novel antibody therapeutics focusing on immunology and oncology, and Insilico Medicine ("Insilico"), a clinical stage generative artificial intelligence (AI)-driven biotechnology company, today announced a strategic collaboration to accelerate the discovery and development of innovative therapeutic antibodies, leveraging their respective technological strengths in antibody discovery and artificial intelligence.

21 Feb 2025

Zinc-carrying proteins may activate PPIs in the absence of gastric acid

Acid reducing medicines from the group of proton pump inhibitors (PPIs) are best-selling drugs that prevent and alleviate stomach problems.

21 Feb 2025

Drug Discovery & Pharmaceuticals

Scientists discover irreversible peptide inhibitors for undruggable cancer target

Sapio Sciences makes AI-Native drug discovery seamless with NVIDIA BioNeMo

UCLA Health discovers drug that mimics stroke rehabilitation effects in mice

Biomanufacturing platform offers a sustainable alternative to synthesizing peptide-based pharmaceuticals

LGM Pharma invests $6 M in U.S. drug manufacturing capabilities for liquids, suspensions, semi-solids, and suppositories

Shift Biosciences announces key appointments to advance rejuvenation therapeutics pipeline

New automated system revolutionizes drug evaluation in zebrafish

British scientists unveil world-leading technology to speed up drug discovery

Vanderbilt researchers aim to use AI to develop antibody therapies for any target

New drug VIP36 shows promise in treating pain without harmful side effects

New chemical reaction enables precise functionalization of peptides and proteins

Microphysiological systems in drug discovery

New antibody-toxin conjugate designed to stimulate immune-mediated eradication of tumors

Insilico Medicine reaches preclinical milestone in MASH drug discovery

New antibiotic design could end the arms race with resistant bacteria

Breakthrough method opens door to fluorinated oxetane drug molecules

New computational tool iDOMO improves prediction of drug synergy

AI-driven discovery unveils TNIK inhibition as anti-aging strategy

Harbour BioMed partners with Insilico to accelerate AI-powered antibody discovery

Zinc-carrying proteins may activate PPIs in the absence of gastric acid

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

The evolution of OCT for retinal imaging and disease intervention

Latest Life Science News